GlassScriptPhysician profile
Denise M Guevara
NPI 1356644264
$23,218.59
in general payments reported to CMS, 2019-2025
39 companies · $12K in 2025
The $12K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,705 · 2020: $1,339 · 2021: $2,285 · 2022: $233 · 2023: $1,668 · 2024: $3,144 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $8,053 · Food and Beverage: $7,924 · Consulting Fee: $590 · Education: $89.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $8,053.40 |
| Food and Beverage | $7,923.89 |
| Consulting Fee | $590.00 |
| Education | $89.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $10,320.09 | 2019-2025 | Ameluz, Bf-Rhodoled, Xepi |
| Abbvie INC. | $2,393.18 | 2019-2025 | |
| Ucb, INC. | $1,371.65 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $1,285.41 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $930.48 | 2019-2025 | Blu-U |
| Incyte Corporation | $719.14 | 2022-2025 | Opzelura, Opzelura |
| Pfizer INC. | $713.63 | 2019-2025 | |
| Lilly USA, LLC | $681.94 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $635.43 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $587.35 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $531.62 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $409.36 | 2019-2025 | Dupixent |
| Vyne Pharmaceuticals INC. | $294.01 | 2020-2021 | |
| Galderma Laboratories, L.P. | $285.56 | 2019-2025 | Nemluvio, Dysport |
| Prugen, INC. Pharmaceuticals | $274.83 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $236.26 | 2023-2025 | Nuzyra |
| Mayne Pharma Commercial LLC | $230.15 | 2019-2023 | |
| Botanix Sb INC | $146.16 | 2025 | Sofdra |
| Janssen Biotech, INC. | $141.95 | 2019-2021 | |
| Dermavant Sciences, INC. | $121.19 | 2023-2024 | Vtama |
| Organon LLC | $99.64 | 2025 | Vtama |
| Celgene Corporation | $85.02 | 2019-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.70 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Arcutis Biotherapeutics, INC. | $74.90 | 2024-2025 | Zoryve |
| Strata Skin Sciences, INC. | $71.24 | 2020-2025 | Xtrac |
| Almirall LLC | $68.77 | 2021-2024 | Klisyri |
| Amgen INC. | $67.32 | 2019-2020 | |
| Kerecis Limited | $55.37 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Organogenesis INC. | $50.55 | 2023-2025 | Cygnus Dual, Puraply |
| Pierre Fabre Pharmaceuticals, INC. | $49.31 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $41.47 | 2019-2021 | |
| Epi Health, LLC | $39.81 | 2019-2020 | |
| Encore Dermatology INC. | $34.51 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.13 | 2025 | Spevigo |
| Dusa Pharmaceuticals, INC. | $18.00 | 2019 | |
| Merck Sharp & Dohme LLC | $16.69 | 2019 | |
| Bioventus LLC | $15.42 | 2022 | |
| Dermira, INC. | $14.35 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Guevara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.